Of the 155 high risk breast cancer patients selected for this study, 20 had germline deleterious mutations in BRCA1 and 13 in BRCA2. The remaining 122 individuals tested negative for BRCA mutations were analyzed for PALB2 germline mutations by direct Sanger sequencing (Table 1) and 13 genetic variants were identified (Table 2). This evidence concerns the gene BRCA2 and breast carcinoma.